Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Moschos

Showing results (81-90 of 88) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 88 results.
Melanoma Research|March 4, 2021
Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922)Stergios J Moschos, Zeynep Eroglu, Nikhil I Khushalani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2015
IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in MelanomaCraig C Carson, Stergios J Moschos, Sharon N Edmiston, et al.
JCI Insight|February 23, 2018
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumorsStergios J Moschos, Ryan J Sullivan, Wen-Jen Hwu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanomaKerstin Trunzer, Anna C Pavlick, Lynn Schuchter, et al.
Immunity|September 26, 2025
Intra-tumoral hypoxia promotes CD8<sup>+</sup> T cell dysfunction via chronic activation of integrated stress response transcription factor ATF4Coral Del Mar Alicea Pauneto, Brian P Riesenberg, Evelyn J Gandy, et al.
The Lancet. Oncology|June 28, 2015
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialAntoni Ribas, Igor Puzanov, Reinhard Dummer, et al.
Frontiers in Oncology|January 22, 2019
The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous MelanomaXiaobei Zhao, Paul Little, Alan P Hoyle, et al.
Plos One|April 3, 2023
InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanomaIrene Orlow, Keimya D Sadeghi, Sharon N Edmiston, et al.
Pageof 9

Showing results (81-90 of 88) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 88 results.
Melanoma Research|March 4, 2021
Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922)Stergios J Moschos, Zeynep Eroglu, Nikhil I Khushalani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2015
IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in MelanomaCraig C Carson, Stergios J Moschos, Sharon N Edmiston, et al.
JCI Insight|February 23, 2018
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumorsStergios J Moschos, Ryan J Sullivan, Wen-Jen Hwu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanomaKerstin Trunzer, Anna C Pavlick, Lynn Schuchter, et al.
Immunity|September 26, 2025
Intra-tumoral hypoxia promotes CD8<sup>+</sup> T cell dysfunction via chronic activation of integrated stress response transcription factor ATF4Coral Del Mar Alicea Pauneto, Brian P Riesenberg, Evelyn J Gandy, et al.
The Lancet. Oncology|June 28, 2015
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialAntoni Ribas, Igor Puzanov, Reinhard Dummer, et al.
Frontiers in Oncology|January 22, 2019
The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous MelanomaXiaobei Zhao, Paul Little, Alan P Hoyle, et al.
Plos One|April 3, 2023
InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanomaIrene Orlow, Keimya D Sadeghi, Sharon N Edmiston, et al.
Pageof 9